Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACSiMiSE-BRAIN
2023-503190-38-00Phase 2Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in multiple sclerosis (MS) comparing Metformin add-on with Placebo add-on (2 arms). Primary endpoint: Change in walking speed (T25FW). Planned start Nov 2023; status: authorised.
02
Drugs
metformin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2023-503190-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503190-38-00.